CMX Research Inc.

CMX Research Inc. is a Canadian full-service contract research organization (CRO) headquartered in Oakville, Ontario. The company positions itself as a preferred CRO for drug and device studies, offering end-to-end clinical trial management for sponsors ranging from early-phase drug development through post-marketing studies. According to its official website, CMX has been operating since 1992 and has completed more than 400 studies, serving clients globally. CMX's service model covers the full clinical trial lifecycle. Its stated project management capabilities include timely ethics submissions, study start-up, budget and contract negotiation, enrollment and patient recruitment, study metrics tracking, electronic data capture (eDC), data query management, advertising campaigns, and study close-out. The company also provides monitoring services through qualified clinical research associates (CRAs) who ensure compliance with ICH GCP standards for Phase I–IV trials as well as bioavailability/bioequivalence (BA/BE) studies. A distinguishing feature of CMX is its investigator network. The company states it maintains an extensive network of clinical trial sites across Canada and the United States, which it describes as the largest network in North America, allowing it to run trials across multiple disciplines and therapeutic areas. Its declared specialty areas include urology, oncology, immunology, cardiology, dermatology, endocrinology, and respirology, along with medical device trials. The company notes that its CEO is a practicing urologist and principal investigator, giving it clinical credibility in its core therapeutic areas. CMX operates primarily in the Canadian and U.S. markets, conducting trials with qualified investigators in Canada and managing multi-site studies across North America. As a privately held company, it does not disclose public financial information. Its value proposition centers on therapeutic specialization, an established investigator network, and a results-focused, sponsor-oriented approach to clinical trial delivery.

CMX Research Inc. was established in 1992 and has since grown into a full-service contract research organization based in Oakville, Ontario, Canada. Over more than three decades of operation, the company reports having completed over 400 clinical studies, building a track record that spans drug development through post-marketing research. From its Canadian base, CMX expanded its reach to serve clients globally, with a particular focus on the North American market. The company developed an extensive network of clinical trial sites across Canada and the United States, which it describes as the largest network in North America. This network enables CMX to manage Phase I–IV trials across multiple therapeutic disciplines and to conduct studies with qualified investigators in Canada. CMX's therapeutic focus has centered on urology, oncology, immunology, cardiology, dermatology, endocrinology, and respirology, alongside medical device trials. The company's leadership includes a CEO who is a practicing urologist and principal investigator, reflecting its roots in clinical practice and its emphasis on investigator relationships. As a privately held company, CMX does not publish financial statements or stock information. Its growth has been driven by its full-service CRO model, covering ethics submissions, study start-up, budget and contract negotiation, enrollment and recruitment, monitoring, electronic data capture, data query management, advertising campaigns, and study close-out. The company continues to position itself as a preferred CRO for drug and device studies, serving sponsors globally from its Canadian headquarters.

• 1992

  CMX Research Inc. founded; begins operating as a contract research organization.

• Completes over 400 clinical studies across Phase I–IV.

• Builds an extensive clinical trial site network across Canada and the USA.

Preferred CRO for drug and device studies, emphasizing therapeutic specialization, an extensive North American investigator network, and full-service Phase I–IV trial management.

• Full-service clinical trial management

  End-to-end management of Phase I–IV trials including ethics submissions, start-up, budgeting, enrollment, monitoring, eDC, and close-out.

• Investigator network services

  Access to an extensive network of clinical trial sites across Canada and the USA for multi-disciplinary trials.

• Monitoring services

  ICH GCP-compliant monitoring by qualified CRAs for Phase I–IV and BA/BE studies.

1. 1Home - CMX Research Inccmxres.com
2. 2CMX Research Inc. (Canada) - Wikidatawikidata.org